Mandate

Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq First North Premier Growth Market

June 04, 2021

Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq First North Premier Growth Market. Trading on Nasdaq First North Premier Growth Market commenced on 4 June 2021.

The price per share in the offering was SEK 34 per share, corresponding to a total value of approximately SEK 2,017 million for all outstanding shares in the Permascand following the completion of the offering. The Offering comprised 14,860,627 shares, corresponding to approximately 25.1 percent of the total number of shares in the company following the completion of the offering, of which 8,823,529 shares were newly issued shares and 6,037,098 shares were existing shares sold by Norvestor VI, L.P. and a few other shareholders

Permascand is an independent technology-driven manufacturer of electrochemical solutions based on proprietary catalytic coatings for cleantech applications. With a customer-centric focus, Permascand has supplied electrodes, electrochemical cells, and aftermarket services to a variety of sectors for the past 50 years.

Vinge’s team consisted of Dain Hård Nevonen, Linnéa Sellström and Eléonore Friberg.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024